Supernus Pharmaceuticals (SUPN) Non-Current Assets (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Non-Current Assets data on file, last reported at $769.1 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $769.1 million, up 16.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 10.03% YoY), and the FY2025 annual result was $808.5 million, up 18.54% from the prior year.
• Non-Current Assets retreated to $769.1 million in Q1 2026 per SUPN's latest filing, from $808.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.1 billion in Q1 2022 and troughed at $643.5 million in Q2 2025.
• A 5-year average of $830.2 million and a median of $808.5 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets decreased 18.98% in 2023, then climbed 18.54% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $968.4 million in 2022, then fell by 18.98% to $784.6 million in 2023, then fell by 13.07% to $682.0 million in 2024, then gained by 18.54% to $808.5 million in 2025, then slipped by 4.86% to $769.1 million in 2026.
• Business Quant data shows SUPN's Non-Current Assets at $769.1 million in Q1 2026, $808.5 million in Q4 2025, and $825.9 million in Q3 2025.